Loss of P16(INK4a) results in increased glucocorticoid receptor activity during fibrosarcoma development by Roca, R et al.
Loss of p16INK4a results in increased glucocorticoid
receptor activity during fibrosarcoma development
Ramon Roca*, Robert M. Kypta†, and Maria d. M. Vivanco*‡
*The Breakthrough Toby Robins Breast Cancer Research Centre at the Institute of Cancer Research, 273 Fulham Road, London SW3 6JB, United Kingdom;
and †Prostate Cancer Research Group, Department of Cancer Medicine, Division of Medicine, Imperial College, Du Cane Road,
London W12 0NN, United Kingdom
Edited by Keith R. Yamamoto, University of California, San Francisco, CA, and approved January 7, 2003 (received for review August 15, 2002)
Glucocorticoids inhibit proliferation of many cell types, but the rela-
tionship between the glucocorticoid receptor (GR) and the proteins
regulating cell cycle progression is not fully understood. We previ-
ously found that during fibrosarcoma (FS) progression, GR displays
only modest transcriptional activity in the preneoplastic stages,
whereas it is highly active in FS cells. Now, we report that glucocor-
ticoids reduce proliferation throughout FS development. The cyclin-
dependent kinase inhibitor p16INK4a is frequently absent in many
cancers, including FSs. We observed that p16INK4a protein expression
is lost at the tumor stage of FS progression. Treatment with the
demethylating agent 5-aza-2-deoxycytidine restores p16INK4a ex-
pression and reverts the phenotype of FS cells to low GR transcrip-
tional activity, similar to that of the p16INK4a-expressing preneoplastic
stages. Importantly, exogenous p16INK4a introduced by cotransfection
is sufficient to reduce GR activity in FS cells, without affecting GR
activity in p16-positive aggressive fibromatosis cells. Furthermore, GR
transcriptional activity is elevated in mouse embryo fibroblasts de-
rived from INK4a/ mice compared with those derived from WT
mice, implying that the difference in p16INK4a expression is sufficient
to modulate GR activity. These results suggest a relationship between
steroid hormone receptor activity and cell cycle inhibition, whereby
absence of p16INK4a protein leads to higher GR transactivation activity
and reduced cell sensitivity to dexamethasone. This observation
might have important implications for current cancer therapies.
G lucocorticoids influence many fundamental biological pro-cesses, from development and homeostasis, to proliferation,
differentiation, and apoptosis (1, 2). In many cell types, they
promote arrest in the G1S transition of the cell cycle, resulting in
a decrease in proliferation (3–5). Although these effects are well
documented, the relationship between the steroid hormone recep-
tors and the cell-cycle regulatory proteins remains unclear (6).
The glucocorticoid receptor (GR) belongs to a superfamily of
transcription factors that includes receptors for steroid and
thyroid hormones, retinoic acid, and vitamin D3 (7). GR is
normally localized in the cytoplasm, in a nonactive state, in a
complex with Hsp90 and other factors. On hormone binding, GR
changes conformation, is released from the complex, and mi-
grates to the nucleus. Once in the nucleus, the receptor can
induce or repress transcription by binding to specific DNA
sequences on target genes.
Progression from the G1 to S phase of the cell cycle is
regulated in part by the activation of cyclin-dependent kinases
(cdk4 and cdk6) by cyclin D1, resulting in phosphorylation of the
retinoblastoma protein (pRb), and consequent release of E2F
transcription factors and expression of genes required for the S
phase (8). Cyclin–cdk complexes are regulated by a family of
kinase inhibitors that can prevent phosphorylation of the cor-
responding substrate (9). p16INK4a (here referred to as p16)
specifically inhibits cyclin D-dependent kinases, preventing them
from phosphorylating and inactivating pRb (10). p16 is often
mutated or inactivated in primary tumors, including leukemias,
melanomas, gliomas, lung carcinomas, osteosarcomas, and fi-
brosarcomas (FSs), and in many cancer cell lines (11–14). Mice
carrying a targeted deletion of the INK4a locus develop spon-
taneous tumors, particularly lymphomas and FSs, at an early age
(15). This phenotype might be the result of the absence of
p19ARF and not p16; however, most of the human mutations
target p16 and not p14ARF (16, 17).
The conversion of a normal cell to a neoplastic one is a multistep
process (18), and one approach to studying this process has used
transgenic mice (19). Mice carrying the bovine papillomavirus
(BPV) type 1 genome develop dermal FSs in a process that involves
distinct proliferative stages. These are the normal dermal fibro-
blasts, and two histological grades of hyperplasia that arise are mild
fibromatosis (MF) and aggressive fibromatosis (AF). Finally, at
lower frequency, dermal FSs develop. Cells cultured from each of
these stages appear to retain characteristics of the lesions from
which they were derived (20). GR displays only modest transcrip-
tional activity in cells derived from the nontumor stages, but is
highly active in FS cells (21). On inoculation into mice, the AF cells
progress to tumor cells with high GR activity, indicating that the
increased GR transcriptional activity correlates with the cellular
transition to the tumor stage (21).
Glucocorticoids are used as part of anticancer therapy for
some lymphatic leukemias and lymphomas (22). In addition,
glucocorticoids have been shown to inhibit in vitro growth of
malignant melanoma cells (ref. 23 and references therein) and
also to inhibit the growth of carcinogen-induced pulmonary
adenoma (24) and FSs (25). To investigate the molecular basis
of the potential antiproliferative role of glucocorticoids in tumor
development, we took advantage of the multistep tumorigenic
pathway that dermal FS development provides and examined the
alterations of the components involved in the G1 phase of
cell-cycle progression and their consequences on GR transacti-
vation activity.
Materials and Methods
DNA Plasmid Constructs. The luciferase reporter TAT3-Luc and
the Rous sarcoma virus (RSV)--gal construct to monitor
transfection efficiency have been described (21). The mouse p16,
p18INK4c, and p19INK4d expression vectors were a generous gift
from Charles J. Sherr (St. Jude Children’s Research Hospital,
Memphis, TN). The expression vectors encoding p21Cip/Waf1 and
p27Kip1 were kindly provided by Sibylle Mittnacht (Institute of
Cancer Research).
Cell Culture and Transient Transfections. Cultures were established
from skin and tumor tissues as reported (21), and maintained in
growth medium (DMEM supplemented with 8% FCS (Auto-
gen). Mouse embryo fibroblasts (MEFs) were generously pro-
vided by Manuel Serrano (National Centre of Biotechnology,
Madrid) and maintained in growth medium (DMEM plus 10%
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FCS). For experiments involving steroid hormone treatments,
growth medium was replaced by medium containing charcoal-
stripped serum (26) 24 h after plating, and cells were treated with
the carrier ethanol, as a negative control, or 100 nM dexameth-
asone (Sigma) for the required amount of time. Cells were
transiently transfected by using the DEAE-dextran method, as
described (21). After exposure to the DNADEAE-dextran
mixture, the cells were incubated for 36 h in fresh medium
containing charcoal-stripped serum, with or without 100 nM
dexamethasone. Luciferase activity was measured according to
the instructions of the manufacturer (Promega) and normalized
for -galactosidase expression.
p16 Expression. First-strand cDNA was synthesized from 0.5 g of
total RNA primed with poly(dT) using Superscript II reverse
transcriptase (Life Technologies). Amplification products for
p16 (145 bp) and GAPDH (200 bp, used as control for RNA
integrity) were generated from the cDNA template. After cDNA
synthesis, 10% of the product from each sample was used for
PCR analysis. Amplifications were carried out in 25-l reaction
volumes for 25 cycles, each consisting of denaturation at 95°C for
1 min, annealing at 60°C for 45 sec, and extension at 72°C for 1
min. Primers were as follows: for p16, 5-AAGCGAACTCGAG-
GAGAGC-3 (sense) and 5-GTACGACCGAAAGAGT-
TCG-3 (antisense); and for GAPDH, 5-TTGTTGCCAT-
CAACGACC-3 (sense) and 5-GACATCATACTTGG-
CAGG-3 (antisense). Water blank, in which no template was
added, was included, and no PCR product was detected in this
control.
For analysis of p16 expression after 5-aza-2-deoxycytidine
(5-Aza-dC) treatment, nested PCR was performed. The oligo-
nucleotides used for the primary PCR to amplify the whole gene
were as follows: 5-TCACACGACTGGGCGATTGG-3
(sense) and 5-GCCATTATTCCCTTCGCCGC-3 (antisense).
Conditions were the same as above, except for extension for 2
min. For the nested PCR, 1 l from the primary reaction was
used with the oligonucleotides amplifying the exon 2 (see below).
Conditions were as for the RT-PCR described above.
Genomic DNA Analysis. Genomic DNA was prepared by using the
Wizard Genomic DNA kit (Promega) according to the instruc-
tions of the manufacturer. It was amplified with primer sets
designed to recognize sequences from the INK4 promoter
region and exon 1: 5-TCACACGACTGGGCGATTGG-3
(sense) and 5-CACCTGAATCGGGGTACGAC-3 (anti-
sense); from exon 2: 5-GGGCAACGTTCACGTAGCAG-3
(sense) and 5-GGCGTGCTTGAGCTGAAGCT-3 (anti-
sense); and from exon 3: 5-CTGGAACTTCGCGGCCAAT-3
(sense) and 5-GCCATTATTCCCTTCGCCGC-3 (antisense);
and for GAPDH as described above. All amplifications were
carried out for 35 cycles using Taq polymerase (Promega) and
the following conditions: an initial 1-min denaturation at 94°C,
annealing at 53°C for 30 sec, and extension at 72°C for 45 sec, in
a thermal cycler (PCR System 9700, Applied Biosystems).
Control water blanks were introduced in each experiment. PCR
products were visualized on 2% agarose gels containing
ethidium bromide.
5-Aza-dC Treatment. Cells were grown in the presence of 5 M
5-Aza-dC for 96 h. Fresh 5-Aza-dC was added every 24 h and the
medium was changed every 48 h. For the transient transfection
experiments, cells were split into six-well plates 48 h after initial
treatment, transfected by using the DEAEdextran method (in
the absence of 5-Aza-dC), and continued with the experiment as
above for the last 36 h of incubation in the absence or presence
of dexamethasone.
Preparation and Analysis of Cell Extracts. Cells were harvested and
whole cell extracts were prepared as described (21). Equal
amounts of protein (30 g) from each cell stage were separated
by electrophoresis on an SDS15% polyacrylamide gel and
transferred to an Immobilon membrane (Millipore). Blocking,
washing, and incubation of the membrane with antibodies were
carried out in Tris-buffered saline (10 mM TrisHCl, pH 7.6150
mM NaCl) containing 4% nonfat dried milk and 0.05% Tween
20. The primary antibodies used were directed against cyclin D1
(72-13G), cdk4 (C-22), p16 (M-156), E2F1 (C-20), cyclin E
(M-20), p18 (N-20), p19 (M-167), p21 (F-5), p27 (F-8) (all from
Santa Cruz Biotechnology), pRb (14001A, PharMingen), and
-tubulin (Sigma). Proteins were detected by using horseradish
peroxidase-conjugated goat anti-rabbit (1:3,000, DAKO), or
goat anti-mouse (1:3,000, Bio-Rad). Protein–antibody com-
plexes were visualized by an enhanced chemiluminescence im-
munoblotting detection system according to the recommenda-
tions of the manufacturer (Amersham Pharmacia).
Results
Dexamethasone Reduces Cell Proliferation at All Stages of FS Pro-
gression. To assess the changes in proliferation during FS pro-
gression we monitored cell growth for 1 wk at 24-h intervals, in
the absence and presence of dexamethasone. The cells from the
earlier stages of the progression proliferated at a low rate,
particularly the NF and MF cells, as reported (20), whereas there
was a very rapid increase in the number of FS cells. Dexameth-
asone treatment resulted in a decrease in the proliferation of the
cells at all stages of FS progression (Fig. 1), likely as a conse-
quence of an accumulation of cells at the G1 phase of the cell
cycle (data not shown). Despite the low levels of GR transcrip-
tional activity in cells from the earlier stages of FS progression,
the inhibition of cell growth by dexamethasone was stronger at
these stages (between 30% and 40% in NF and MF cells) than
at the FS stage (11%), suggesting that FS cells have partially
Fig. 1. Effect of dexamethasone (dex) on proliferation of cell lines from
different stages of FS progression. Cell-growth kinetics of NF (NF 40950, MF
14249, and AF BPV3) and FS cells (FS BPV1). Cells from each stage were plated
on day 0 onto six-well plates, and cultured in the absence () or presence ()
of 100 nM dexamethasone. Total numbers of viable cells were determined on
the indicated days by the trypan blue exclusion method. The graph represents
one of at least three independent experiments, which were done in triplicate.
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overcome the growth-inhibitory pathways mediated by GR. In
conclusion, as documented in many other cell types, dexameth-
asone reduces cell proliferation during FS development.
p16 Protein Is Absent at the Tumor Stage of FS Progression. To
further investigate the effects of dexamethasone on cell prolif-
eration, we examined the expression of various proteins involved
in cell-cycle regulation by immunoblot analysis. The expression
levels of cyclin D1, cdk4, and E2F1 were not affected by FS
progression or dexamethasone treatment (Fig. 2A). pRb mobility
was slightly decreased at the tumor stage, probably reflecting the
increased pRb phosphorylation that accompanies increased cell
cycling, but pRb mobility was not affected by dexamethasone.
There was a small increase in cyclin E levels in FS cells, possibly
as a consequence of the increased level of pRb phosphorylation
at the tumor stage of FS development. The most striking
observation during this analysis was that the expression of p16
protein was completely lost during the transition from the AF to
the FS stage. However, the expression of p16 was not influenced
by dexamethasone treatment at any of the preneoplastic stages
(Fig. 2 A). Expression of p16 protein was also found in a second
set of clones that were tested corresponding to NF, MF, and AF
stages (Fig. 2B), independent of their passage number, but was
not observed in any of the four clones that were examined
corresponding to the FS stage (Fig. 2B and data not shown). This
result indicates that the loss of p16 protein at the tumor stage is
inherent to the transition from the AF to the FS stage during FS
progression. In contrast, the expression levels of other cdk
inhibitors, including members of the INK4 family (p18INK4c and
p19INK4d), and members of the CipKip family (p21Cip/Waf1 and
p27Kip1), were unchanged during FS development (Fig. 2B).
p16 Coding Region Is Present in FS Cells. To investigate whether the
lack of p16 protein coincides with the absence of mRNA
expression, we performed RT-PCR analysis using mRNA from
all stages of FS progression. p16 mRNA was present in NF, MF,
and AF cells, but not in FS cells (Fig. 3A), which was found to
be similar to p16 protein expression levels during FS develop-
ment. The lack of p16 protein and mRNA expression in FS cells
raised the possibility that p16 DNA might be lost, mutated, or
inactivated. Homozygous deletions represent a mechanism of
p16 inactivation in various types of tumors (11, 27). We used
PCR analysis to examine the genomic DNA from cells repre-
senting all stages of FS progression to determine whether any of
the exons were selectively deleted in FS cells. By using oligonu-
cleotides that hybridized with regions of exons 1, 2, and 3 (28),
specific 200-, 350-, and 250-bp (respectively) products were
amplified in all samples obtained from each stage of FS devel-
opment (Fig. 3B). These products represent the whole coding
region of mouse p16, and, therefore, they demonstrate that the
DNA encoding p16 is not deleted in FS cells.
Methylation Modulates GR Transactivation Activity. In addition to
homozygous deletion and rare inactivating mutations, several
recent studies have identified inappropriate methylation of exon
1 and the 5 promoter region of p16 in cell lines and tumors
derived from both humans and mice (29, 30). One possibility of
this finding is that the p16 gene is inactivated by methylation at
the FS stage, as does occur in many other tumor cell types,
including FSs (31, 32). Because the only documented molecular
change in the progression from AF to FS is the increased
transactivation activity of GR (21), we sought to determine
whether there was a link between GR transcriptional activity and
p16 inactivation predicted to result from methylation. To this
end, we treated the cells with the DNA methyltransferase
inhibitor 5-Aza-dC, which has been reported to demethylate the
Fig. 2. Expression of cell-cycle regulatory proteins during FS progression. (A)
Cells from each stage (clones as indicated in Fig. 1) were cultured in the
absence () or presence () of 100 nM dexamethasone for 48 h. Whole-cell
extracts were probed with antibodies against cyclin D1, cdk4, pRb, p16, E2F1,
and cyclin E (antibodies were used as described in Materials and Methods).
Each immunoblot is representative of at least three independent experiments.
(B) Intracellular levels of various cdk inhibitors during FS progression. A second
set of clones, different from the set used above, and representative of each
stage of FS progression (NF non-BPV, MF 39614, AF BPV7, and FS BPV22,
represented by N, M, A, and F, respectively) were used in this experiment. Each
blot was reprobed for -tubulin as a control for equal loading (data not
shown). Note that the apparent increase of p18 expression in FS cells was
insignificant after correction with tubulin levels.
Fig. 3. RT-PCR and PCR analysis of p16 expression throughout FS progres-
sion. (A) Detection of p16 mRNA by RT-PCR analysis in samples obtained from
NF, MF, AF, and FS cells. (B) PCR analysis of genomic DNA from NF, MF, AF, and
FS cells. The oligonucleotides were designed to hybridize with sequences from
each exon of the mouse p16 coding region (28). A PCR without template (H2O)
was incorporated in the analysis as a negative control.
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p16 gene promoter, leading to reexpression of p16 (12, 30, 33,
34). AF (expressing p16) and FS (not expressing p16) cells were
grown in the presence or absence of 5-Aza-dC treatment and
were transfected with the luciferase reporter construct TAT3-
Luc, which contains three copies of a simple glucocorticoid
response element (21). The results from these transfection
experiments (Fig. 4A) revealed that 5-Aza-dC has no significant
effect on the hormone responsiveness of AF cells. In contrast,
treatment with 5-Aza-dC strongly reduced GR transcriptional
activity in FS cells, compared with the results observed in AF
cells.
To directly address whether treatment with the demethylating
agent 5-Aza-dC resulted in the reexpression of p16 in FS cells,
we performed RT-PCR analysis. Expression of p16 mRNA was
restored in FS cells (Fig. 4B) on treatment with 5-Aza-dC,
suggesting that the observed effect on GR activity (Fig. 4A) is
because of p16 reactivation. These observations support a model
in which inactivation of p16 by methylation results in increased
GR transcriptional activity in FS cells.
p16 Affects GR Transcriptional Activity and Cell Sensitivity to Dexa-
methasone. To assess whether expression of p16 protein is
sufficient to reduce GR transcriptional activity, we cotransfected
a p16 expression vector together with the simple glucocorticoid
response element reporter, TAT3-Luc, into AF and FS cells.
Over a wide range of cotransfected p16 expression vector, no
statistically significant difference in GR activity was detected in
AF cells (Fig. 5A). In contrast, cotransfected p16 clearly reduced
the magnitude of the dexamethasone response in the FS cells.
Importantly, the same results were obtained with three different
AF and FS clones we tested, indicating that the reduction of GR
transcriptional activity by exogenously expressed p16 is a general
phenomenon in FS cells. Notably, cotransfected RSV--gal
produced comparable -galactosidase levels throughout the
experiment (data not shown), indicating similar transfection
efficiencies. In conclusion, ectopic expression of p16 is sufficient
to repress GR transcriptional activity. In contrast, cotransfection
of expression vectors encoding other cdk inhibitors, including
members of the INK4 family (p18INK4c and p19INK4d), and
members of the CipKip family (p21Cip/Waf1 and p27Kip1), did not
significantly affect GR transcriptional activity in AF or FS cells
(Fig. 5B).
To determine whether endogenous p16 protein affects GR
transcriptional activity, we compared the hormone responsive-
ness of WT and INK4a/ MEFs. We tested three different
clones for each type and, interestingly, all INK4a/ MEFs
displayed higher GR transcriptional activity compared with WT
MEFs (Fig. 5C). Taken together, these findings imply that p16
inhibits GR activity and that loss of p16 in FS cells results in
elevated GR transcriptional activity.
Fig. 4. Methylation modulates GR-mediated transcriptional activity in FS
cells. (A) AF and FS cells were grown in the absence () or presence () of 5M
5-Aza-dC for 96 h, and the expression from the TAT3-Luc reporter was deter-
mined in the absence or presence of 100 nM dexamethasone. Luciferase
activity was normalized against a cotransfected -galactosidase reporter. The
values presented are the average of at least three independent experiments,
which were done in triplicate. (B) Detection of p16 mRNA by RT-PCR analysis
in AF cells in the absence of 5-Aza-dC treatment, but not in FS cells. Treatment
of FS cells with 5 M 5-Aza-dC during an increasing amount of time (h) results
in the reexpression of p16 mRNA.
Fig. 5. Effects of p16 expression on GR transcriptional activity and the
antiproliferative effects of dexamethasone. (A) Effects of cotransfected p16
on hormone responsiveness of AF and FS cells. Expression from the TAT3-Luc
reporter in AF and FS cells in the absence (0) or presence of exogenous p16. A
wide range of p16 plasmid was tested (0, 0.1, 0.75, and 1.5 g are shown).
Transfected cells were cultured for 36 h in the absence (solid bars) or presence
(shaded bars) of 100 nM dexamethasone. Luciferase activity was normalized
against a cotransfected-galactosidase reporter. The values presented are the
average of at least three independent experiments, which were done in
triplicate. (B) Effects of cotransfected p18INK4c, p19INK4d, p21Cip/Waf1, and
p27Kip1 on hormone responsiveness of AF and FS cells. A wide range of
concentrations was tested and the cotransfection of 0.75 g of each expres-
sion vector is shown as representative example. Cotransfection of the expres-
sion vector without insertion of the sequences encoding the different cdk
inhibitors is represented as ‘‘empty.’’ The conditions were as in A. (C) GR
transcriptional activity in MEFs derived from WT or INK4a/ mice. The TAT3-
Luc was transfected into three different cell lines derived from WT (clones 41,
42, and 44) and INK4a/ (clones 35, 36, and 37) mice. The cells were untreated
(solid bars) or treated with dexamethasone (shaded bars). Conditions were as
in A. (D) Relative cell number of WT () and INK4a/ ({) MEFs treated with
dexamethasone versus those that were untreated. The conditions were as in
Fig. 1.
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Finally, we wished to investigate whether there is a relation-
ship between GR transcriptional activity and the antiprolifera-
tive effects of dexamethasone that depends on the presence of
p16. We were unable to generate FS lines stably expressing p16.
This result is, perhaps, not surprising, taking into account the
expected growth arrest imposed by overexpression of p16. To
determine the effects of dexamethasone specifically caused by
the expression of p16, we examined the effects of dexamethasone
the cell growth of MEFs, both WT and INK4a/. Interestingly,
WT MEFs were more sensitive (between 15% and 20%) to the
growth inhibitory effects of dexamethasone than were MEFs
lacking p16 (Fig. 5D). This finding resembles the higher sensi-
tivity to dexamethasone of NF, MF, and AF cells with respect to
FS cells (see Fig. 1). These results suggest that loss of p16
influences the cellular response to the antiproliferative effects of
dexamethasone.
Discussion
Control of cell proliferation is deregulated in the majority of
tumors (for a review, see ref. 35). Proliferation increases during
FS development in vivo (36), and in cultured cells (20), partic-
ularly at the FS stage. We observed that dexamethasone reduces
cell proliferation throughout the progression; however, this
reduction is more apparent in the earlier stages of tumorigenesis
than at the FS stage. At the FS stage, duplication of chromosome
8 andor loss of chromosome 14 are observed (37), and it is
therefore possible that some factor lies in the duplicated or
deleted regions that might overcome the effects of dexametha-
sone on cell-cycle regulation. The BPV1 genome acts as a
tissue-specific oncogene in transgenic mice, and its transforming
properties reside mainly in two genes, E5 and E6, whose products
are detectable in AF and FS cells to similar levels, suggesting that
increased levels of the oncoproteins are not responsible for the
step from AF to FS (20). Another possibility is that in FS cells
the reduction in apoptosis in response to dexamethasone (D.
Gascoyne and M.d.M.V., unpublished observations), to those
levels found in cells from earlier stages of tumorigenesis, miti-
gates the effects on proliferation. Thus, the final step to FS
development is accompanied by an altered proliferationapo-
ptosis ratio in favor of proliferation. Importantly, our studies of
cell-growth inhibition by dexamethasone using WT and
INK4a/ MEFs identifies the loss of p16 as a molecular change
that renders cells less sensitive to the antiproliferative effects of
dexamethasone.
p16 expression was lost in four different FS lines tested,
whereas p16 was detected in all of the cell lines examined from
each stage of the tumorigenic pathway, independent of the
passage number (note that the cells were used only at low
passage numbers, 1–30). This finding suggests that inactivation
of p16 is a late event in FS progression and coincides with the
high increase in proliferation of FS cells and the transition in
transcriptional activation by GR at the tumor stage of FS
development (21). In some cases, inactivation of p16 has been
found to be an early event during tumorigenesis (12, 38, 39);
although in brain tumors (40), and lung carcinomas (41), later
stage tumors present higher frequencies of p16 abnormalities,
suggesting that different tumor types present different progres-
sion events to malignancy.
FS cells do not express p16 mRNA, suggesting that a non-
transcriptional mechanism is responsible for the loss of p16 in FS
cells. Because p16 genomic DNA can be detected at all stages of
FS progression, it is unlikely that deletions in the p16 coding
region have occurred in FS cells. These observations lead us to
favor the possibility that the loss of p16 in FS cells involves
methylation of the p16 promoter. Indeed, methylation of the 5
CpG island in the p16 promoter is a frequent mechanism of p16
inactivation in many tumor types (42), and, importantly, in FSs
(31, 32). Interestingly, and consistent with this hypothesis,
inhibition of DNA methylation by treatment with 5-Aza-dC
restores p16 expression in FS cells and reduces GR transcrip-
tional activity in FS cells, but not in AF cells. Thus, a reduction
in methylation results in decreased GR transcriptional activity.
We carried out two sets of experiments that specifically
addressed whether the level of p16 expression influences GR
transcriptional activity and obtained the following results. First,
ectopic expression of p16 specifically inhibits GR activity in FS
cells. Second, MEFs in which the p16 gene has been deleted
exhibit increased GR activity relative to their normal counter-
parts, further supporting a model in which endogenous p16
normally represses GR transcriptional activity, and loss of p16
leads to GR activation.
Conditional expression of p16 in a lymphoblastic leukemia cell
line has recently been reported to be associated with enhanced
glucocorticoid-mediated transcriptional activity as a result of
increased GR protein levels (43). In contrast, during FS devel-
opment, the level of GR protein expression remains constant,
whereas there is an increase in the transcriptional activity of GR
at the tumor stage (21); and GR protein expression levels are
clearly not affected by the absence (FS cells) or presence (NF,
MF, and AF) of p16. This discrepancy highlights how p16 effects
on GR might be different, depending on the cell type investi-
gated. In this context, the role of glucocorticoids in inducing
apoptosis in leukemic cells is well established (44). However,
they inhibit apoptosis in other systems (45–47), including FS
progression (D. Gascoyne and M.d.M.V., unpublished observa-
tions). The contrasting effects of glucocorticoids on apoptosis in
the lymphoblastic leukemia cells and FS cells parallel those of
p16 expression on GR transcriptional activity in these two
cellular contexts. This finding might reflect the variety of
alterations that give rise to cancers in different tissues.
p16 specifically binds to cdk4 and inhibits cdk4-dependent phos-
phorylation of pRb and progression to the S phase of the cell cycle
(48). The analysis of mutations found in human tumors suggests
that cyclin D1, cdk4, pRb, and p16 are critical components of a
cell-cycle regulatory pathway that is altered in most tumor cells
(reviewed in ref. 49). Differences among cell types have been
reported for cell-cycle proteins involved in GR-mediated cell-cycle
arrest. For example, cdk4 and E2F protein levels are repressed by
GR in U2OS cells, but not in SAOS cells (50). We observed a
constant level of expression of cyclin D1 and cdk4 during FS
progression. The dramatic loss of p16 expression from AF to FS is
reflected by a change in pRb mobility, suggesting increased phos-
phorylation and, therefore, increased proliferation. Interestingly,
pRb potentiates GR transcriptional activity through the interaction
of pRb’s pocket domain with the transcriptional coactivator hBRM
(51), whereas hBRM can potentiate the transcriptional activity of
GR (52). It remains to be determined whether increased phos-
phorylation of endogenous pRb (through lack of p16) increases GR
transcriptional activity. Interestingly, other cdk inhibitor proteins,
including members of the INK4 family (p18INK4c and p19INK4d), and
members of the CipKip family (p21Cip/Waf1 and p27Kip1), were
expressed at similar levels throughout FS development and, there-
fore, it is not surprising that their overexpression did not signifi-
cantly affect GR transcriptional activity in AF or FS cells. This
result suggests that the effects of p16 on GR activity are specific.
The identification of the differential transcriptional activity
displayed by GR at the critical FS stage was the first molecular
parameter to distinguish AF from FS (21). The loss of p16
expression provides a second molecular parameter. Although it
is presently unclear how the loss of p16 leads to GR activation,
this observation might have important implications for current
cancer therapies. For example, treatment of malignant lympho-
proliferative disorders by using dexamethasone (53) may have
different clinical outcomes, depending on whether the cancer
cells express p16. The correlation between activation of GR,
sensitivity to the antiproliferative effects of dexamethasone, and
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the loss of p16 highlights a functional relationship between
steroid hormone receptors and cell-cycle inhibitors.
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